Your browser doesn't support javascript.
loading
Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology.
Raggi, Paolo; Milic, Jovana; Manicardi, Marcella; Cinque, Felice; Swain, Mark G; Sebastiani, Giada; Guaraldi, Giovanni.
Afiliação
  • Raggi P; Department of Medicine and Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada. Electronic address: raggi@ualberta.ca.
  • Milic J; Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy.
  • Manicardi M; Cardiology Department, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
  • Cinque F; SC-Medicina Indirizzo Metabolico, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan, Department of Pathophysiology and Transplantation, University of Milan, Italy; Division of Gastroenterology and Hepatology and Chronic Viral Illness Service, McGill University Health Centre, Montrea
  • Swain MG; Department of Medicine, University of Calgary Liver Unit, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Sebastiani G; Division of Gastroenterology and Hepatology and Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada; Division of Experimental Medicine, McGill University, Montreal, QC, Canada.
  • Guaraldi G; Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.
Atherosclerosis ; 392: 117523, 2024 May.
Article em En | MEDLINE | ID: mdl-38522165
ABSTRACT
Altered metabolic function has many detrimental effects on the body that can manifest as cardiovascular and liver diseases. Traditional approaches to understanding and treating metabolic dysfunction-associated disorders have been organ-centered, leading to silo-type disease care. However, given the broad impact that systemic metabolic dysfunction has on the human body, approaches that simultaneously involve multiple medical specialists need to be developed and encouraged to optimize patient outcomes. In this review, we highlight how several of the treatments developed for cardiac care may have a beneficial effect on the liver and vice versa, suggesting that there is a need to target the disease process, rather than specifically target the cardiovascular or liver specific sequelae of metabolic dysfunction.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Cardiologia / Gastroenterologia Limite: Humans Idioma: En Revista: Atherosclerosis Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Cardiologia / Gastroenterologia Limite: Humans Idioma: En Revista: Atherosclerosis Ano de publicação: 2024 Tipo de documento: Article